Ocular Therapeutix (OCUL) Misses Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
Ocular Therapeutix™ Reports Fourth Quarter and Year End 2018 Financial Results and Business Update
March 7, 2019 4:01 PM ESTDEXTENZA® Commercial Launch Planned for Mid-Year 2019
OTX-TP Phase 3 Data Expected in the First Half of 2019
Strengthened Cash Position with Closing of $37.5 Million Financing
BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the fourth quarter and year ended December 31, 2018 and provided a business update.
2018 was a transformational year for Ocular highlighted by the U.S. Food and... More
